Search research articles
Contact Us
Filters
Showing results (101-110 of 132) with videos related to
Page
of 14
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
June 7, 2020
Cumulative pemetrexed dose increases the risk of nephrotoxicity
N de Rouw, R J Boosman, H van de Bruinhorst, et al.
British Journal of Clinical Pharmacology
|
November 26, 2004
Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers
C J L la Porte, M J A de Graaff-Teulen, E P H Colbers, et al.
Therapeutic Drug Monitoring
|
August 15, 2000
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir
P W Hugen, D M Burger, M de Graaff, et al.
Tropical Medicine & International Health : TM & IH
|
December 17, 2017
Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics
E J Smolders, N Thammajaruk, C T M M de Kanter, et al.
British Journal of Clinical Pharmacology
|
March 26, 2018
A pharmacological rationale for improved everolimus dosing in oncology and transplant patients
R Ter Heine, N P van Erp, H J Guchelaar, et al.
Antiviral Therapy
|
June 22, 2001
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial
N A Foudraine, S Jurriaans, G J Weverling, et al.
Cancer Chemotherapy and Pharmacology
|
October 4, 2024
A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed
N de Rouw, R Beunders, O Hartmann, et al.
HIV Medicine
|
March 28, 2008
Steady-state nevirapine plasma concentrations are influenced by pregnancy
J F J B Nellen, M Damming, M H Godfried, et al.
Antimicrobial Agents and Chemotherapy
|
February 22, 2001
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children
D M Burger, A M van Rossum, P W Hugen, et al.
Clinical Pharmacology and Therapeutics
|
December 23, 2011
Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1
P Kasirye, L Kendall, K K Adkison, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 132) with videos related to
Sort By:
Page
of 14
Lung Cancer (Amsterdam, Netherlands)
|
June 7, 2020
Cumulative pemetrexed dose increases the risk of nephrotoxicity
N de Rouw, R J Boosman, H van de Bruinhorst, et al.
British Journal of Clinical Pharmacology
|
November 26, 2004
Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers
C J L la Porte, M J A de Graaff-Teulen, E P H Colbers, et al.
Therapeutic Drug Monitoring
|
August 15, 2000
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir
P W Hugen, D M Burger, M de Graaff, et al.
Tropical Medicine & International Health : TM & IH
|
December 17, 2017
Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics
E J Smolders, N Thammajaruk, C T M M de Kanter, et al.
British Journal of Clinical Pharmacology
|
March 26, 2018
A pharmacological rationale for improved everolimus dosing in oncology and transplant patients
R Ter Heine, N P van Erp, H J Guchelaar, et al.
Antiviral Therapy
|
June 22, 2001
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial
N A Foudraine, S Jurriaans, G J Weverling, et al.
Cancer Chemotherapy and Pharmacology
|
October 4, 2024
A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed
N de Rouw, R Beunders, O Hartmann, et al.
HIV Medicine
|
March 28, 2008
Steady-state nevirapine plasma concentrations are influenced by pregnancy
J F J B Nellen, M Damming, M H Godfried, et al.
Antimicrobial Agents and Chemotherapy
|
February 22, 2001
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children
D M Burger, A M van Rossum, P W Hugen, et al.
Clinical Pharmacology and Therapeutics
|
December 23, 2011
Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1
P Kasirye, L Kendall, K K Adkison, et al.
Page
of 14